Canadense

porra, quer empurrar pro meu lado??? sempre sobra pra mim...

http://www.ctvnews.ca/health/pot-or-not-why-parents-of-kids-with-epilepsy-want-access-to-marijuana-treatment-1.1372695 http://www.ctvnews.ca/video?clipId=968241 Desperate parents of children with severe forms of epilepsy are starting to demand access to an unusual and experimental treatment made from marijuana. But many doctors in Canada are saying that until there is more evidence that the treatment is actually helpful, they’re not going to be recommending it to patients. Fifteen-year-old Teigan Janfield has suffered from severe epileptic seizures her whole life. She has a rare genetic disorder called Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), which causes her to have several seizures a day. "It's horrible and heartbreaking to see this repeatedly,” her mother Paula Janfield told CTV News. None of the 14 medications that have been prescribed to Teigan over her lifetime have stopped the seizures. Now, her mother is hoping to get her an experimental treatment called CBD, or cannabidiol. The drug is a liquid marijuana extract that many say helps to stop the seizures. CBD comes from a strain of cannabis that is high in cannabidiol but low in THC, the compound in marijuana that brings on the “high” of pot-smoking. Advocates of the treatment say it calms the brain without intoxicating children. CBD is legal for children in some U.S states, including Colorado, but parents in Canada can't get the extract because they can’t find doctors who will prescribe it. Still, many parents in the U.S. report CBD has dramatic results. California father Jason David says he has been giving CBD to his six-year-old son Jayden, who also has Dravet Syndrome. He says Jayden has been seizure-free for nine months. Advocates like Dr. Margaret Gedde of the Clinicians’ Institute for Cannabis Medicine say CBD can significantly change the lives of children with epilepsy. “They can eat. They can put on weight. They can sleep,” she said. “They can actually have a normal childhood.” But others, including neurologist and pediatric epilepsy expert at Toronto’s Hospital for Sick Children Dr. Berge Minassian, say there's little scientific proof that CBD is either safe or works. “If any doctor had used it and seen it work, it would have been published as a case report (in a medical journal). There are is no case report in the literature,” Minassian told CTV News. Dr. Orrin Devinsky, the director at New York University and Saint Barnabas Epilepsy Centers, says there have been some animal studies that have shown CBD reduces seizures, but he remains skeptical. “Many therapies which start out with excitement turn out not to work,” he says. Still, Devinsky has received approval from the FDA to begin a new study in the next few months to test the safety of CBD in children with Dravet Syndrome. “Then, we will move into studies to see if it is effective,” he says. The results of that research could take several years. In the meantime, many parents of kids with severe epilepsy say their children should be allowed to try the treatment on compassionate grounds because, so far, nothing else is working. Tiegan’s mother Paula is one of those who want to access the treatment, as she worries about the effects of her daughter’s epilepsy. “We know seizures can cause brain damage,” she says. “This is something we needed yesterday.” Barry Pogson, whose nine-month old daughter Kate has already suffered more than 50 seizures, said CBD could offer an alternative to emergency medicines that often don’t work. “It is scary when you run out of things to give her,” Pogson said. “It’s terrifying.” Kate’s seizures can last up to an hour and Pogson said he worries that one of them might be fatal or that his daughter will suffer long-term brain damage. In a statement, Health Canada said people can apply for access to marijuana for medical purposes if they meet certain criteria, and the agency has a contract with Prairie Plant Systems Inc. to produce a “reliable, standardized source” of marijuana for patients who qualify. However, Health Canada said “while there are many anecdotal reports of the therapeutic value of marijuana, as well as different strains of marijuana, scientific evidence does not establish the safety and efficacy of cannabis to the extent required by the Food and Drug Regulations for marketed drugs in Canada. “Therefore, it is not an approved therapeutic substance in Canada.” The agency said new regulations will come into effect on April 1, 2014, allowing individuals to get marijuana directly from licensed producers. The new rules will not restrict those producers to any one strain of marijuana and there will be no restrictions on THC or CBD levels. Health Canada said three prescription medications containing THC, a THC derivative or TCH with other cannabinoids have received “notice of compliance and market authorization.” Those medications are dronarbinol (Marinol), nabilone (Cesamet) and Sativex.

pq vc nunm ta usando DABS.... vou falar pro 6... em casa num fumo maconha faz quase 5 anos... so nos dabs

maluco, num existe presidio no mundo que num tem maconha.

http://jmonline.com.br/novo/?noticias,5,pol%CDcia,83138 Polícia localiza plantação de maconha em quarto de jovem ser flagrado cultivando maconha em casa no bairro Boa Vista. Segundo a Polícia Militar, L.C.B.G., 23 anos, plantava a droga dentro do quarto, com todo equipamento de irrigação e iluminação. Ele afirmou ter aprendido e comprado tudo pela internet. No imóvel foram apreendidos 28 pés de maconha, que, segundo o acusado, seria para uso próprio. A polícia recebeu informações de que o suspeito estaria cultivando pés de maconha em uma residência na rua Antônia Tavares. De posse da informação, a viatura da Rotam, comandada pelo sargento Caio, foi até o local. Os militares fizeram campana no endereço e abordaram o suspeito no momento em que ele saía para passear com o cachorro. Questionado, o jovem confessou que cultivava a droga em casa e que era para uso próprio. Os militares entraram no imóvel com autorização do pai do suspeito e, no quarto do jovem, se depararam com uma espécie de laboratório. “O quarto tinha irrigação e iluminação adequadas. O pai afirmou, inclusive, que sabia desta prática do filho”, afirmou o sargento. O suspeito afirmou, segundo a PM, que aprendeu a técnica na internet, por onde também teria comprado o material usado para plantação da maconha. “Ele nos mostrou um site que explicava desde a compra da semente até a técnica de plantação: quanto tempo deve ficar no escuro ou com a luz acesa, os produtos para adubar e o período em que a planta deve ser irrigada”, revelou o militar. A PM encontrou ainda uma espécie de organograma impresso em duas folhas. “Era tudo muito organizado e explicava todo o procedimento. O suspeito disse ainda que a droga tinha que ser tratada com carinho e dedicação porque assim ela iria adquirir força para ser consumida”, salientou o policial. De acordo com o sargento Caio, o site também orientava quem faz o cultivo da droga a como agir, caso fosse surpreendido pela polícia. “No site está em destaque, em letras maiores, em negrito e em vermelho como proceder quando for abordado pela polícia: ‘diga sempre que a droga é para uso próprio’”, contou o policial. Além da droga, foram apreendidos ainda o material para adubo e os sistemas de irrigação e iluminação. O suspeito foi levado à delegacia para prestar esclarecimentos. EDIT: E solto em seguida...

Meu favorito é quando eles soltam um "may cause anal leakage" no fim do commercial...

ADHD ADD non existem

maluco... Eu tou perto da fronteira com os EUA entao sempre vejo TV dos cara... Mano, os commerciais deles sao 80% remedios. e num e tylenol nao, bagulho tarja preta...

nunca sabia dessa porra antes de hj

http://en.wikipedia.org/wiki/Rimonabant Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti,[3] and Riomont) is an anorectic antiobesity drug that has been withdrawn from the market. It is an inverse agonist for the cannabinoid receptor CB1.[4] Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it was indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients with a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it was available beginning in July 2006. As of 2008, the drug was available in 56 countries. On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended.[5][6] Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.[7] Contents [hide] 1 History 2 Side effects 3 Other uses 3.1 Smoking cessation 3.2 Addiction 3.3 Memory 3.4 Blockage of cannabis effects 3.5 Effect on physical activity 3.6 Effect on male fertility 4 Reaction 5 References History[edit] See also: Discovery and development of Cannabinoid Receptor 1 Antagonists The French pharma firm Sanofi-Aventis disclosed a complete response to the FDA's approvable letter was submitted on 26 October 2006, triggering a Class I (two-month) or Class II (six-month) review process. On 13 June 2007, FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval.[2] Subsequently, Sanofi-Aventis announced it was suspending the new drug application (NDA) for rimonabant, and that it would resubmit an application at some point in the future. On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union. Sanofi announced the first country in which Acomplia would be sold was the United Kingdom as a prescription drug. Sales began in July 2006. Sanofi also announced it projected that the drug would be sold shortly thereafter in Denmark, Ireland, Germany, Finland, and Norway. It was expected in Belgium[8] and Sweden in 2007. Ordinary obesity would, according to official medical recommendations, not be enough to acquire the prescription in Sweden; there would be additional requirements concerning abnormal blood lipid levels.[9] The EU's approval was not a blanket approval, nor did it approve Acomplia for nonobesity-related problems, such as smoking cessation, although off-label use of the drug was still possible. The approval was, in combination with diet and exercise, for the treatment of obese patients (BMI greater than or equal to 30), or overweight patients (BMI greater than 27) with associated risk factors, such as type 2 diabetes or dyslipidaemia. In October 2008, the European Medicines Agency recommended doctors not prescribe the drug due to the risk of serious psychiatric problems and even suicide. The drug was subsequently suspended.[1] Side effects[edit] Shortly after market introduction, press reports and independent studies suggested side effects occurred more intensely and more commonly than shown by the manufacturer in their clinical studies. Resulting from drug actions at CB1 receptors in the brain, reports of severe depression and suicidal thoughts are frequent.[10] As CB1 receptors are fairly ubiquitous throughout the central nervous system, it is not currently understood where exactly the inverse agonist is acting to cause these side-effects. On 15 June 2007, BBC News reported[11] a committee advising the U.S. FDA had voted not to recommend the drug's approval because of concerns over suicidality, depression, and other related side effects associated with use of the drug. Other uses[edit] Smoking cessation[edit] Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi-Aventis that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".[12] Addiction[edit] Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans: priming and cues. It may also reduce ethanol- and opiate-seeking behavior.[13] Memory[edit] Tetrahydrocannabinol (THC) is known to impair short-term memory. It was therefore hypothesised that rimonabant may improve short-term memory. Indeed, in animal studies, it significantly improved the performance of rats to encode information in the short-term memory.[14] Blockage of cannabis effects[edit] Rimonabant blocks the psychoactive and some of the cardiovascular effects of Δ9-tetrahydrocannabinol (THC) in humans without affecting the pharmacokinetics.[15] Rimonabant has been described colloquially as "reverse marijuana", having a depressing effect on appetite analogous to the increased appetite created by cannabinoids.[16] Effect on physical activity[edit] Rimonabant reduces voluntary wheel running in laboratory mice.[17] Effect on male fertility[edit] Rimonabant significantly increased human sperm motility and viability in vitro.[18] Reaction Rimonabant can be synthesized as follows:[19]

po... louco é fazer um tour na fabrica na heineken... tomar uma ice heine é da hr... e um boteco muito louco é o Lux

na boa... bial, volta la pra de tras da mesa de jornal que e a tua... deixa essas coisas Serginho Groisman pra quem sabe

po estive gripado... melhoro e volto com uma noticia dessa... que beleza!

Foi esse swing... nao o outro..... o outro ta certissmo

... tb

... foi msm... mas ai... EU ponho o sexo na palavra deslexico...

cara... esse palavra swing, como usado no brasil, me encomoda um tanto... a palavra certa seria funk... nao swing ou suingue, como queiram...

The European Court of Human Rights on June 27th ordered France to pay compensation to three drug traffickers. File photo: Bertrand Guay/AFP http://www.thelocal.fr/20130627/france-must-compensate-convicted-drug-traffickers-court France ordered to pay drug traffickers damages The European Court of Human Rights ruled on Thursday that the traffickers' human rights had been breached because the French authorities did not put the crew of the Panama-registered freighter "Junior" immediately before a judge after they had been escorted to Brest in Britanny. Intercepted off the coast of Africa in 2008, the "Junior" took 18 days to reach the western port. The crew were then placed in custody for two days before being put before a judge who decided to extend their detention. That was a breach of their rights, the ECHR's judges decided, because the French authorities could have been able to ensure a hearing as soon as the "Junior" reached shore. Seven members of the ship's crew were sentenced in 2012 to prison sentences of between 10 and 25 years for their role in shipping a cargo with an estimated street value in excess of 100 million euros ($130 million) from Brazil to Algeria. Their convictions are currently being reviewed at an ongoing appeal hearing.

que 180º mais doido

NCP num conheo mas ja queimei um do conciousness.... meul deuls!!!!

a e... agua e essencial... ate no bho fica mais liquido

lembrando que quando esquentado , a viscosidade diminui...

e mermao... tem que ter culhao pra vender... pra plantar e vender tem que ter bolas de aco... gracas ateus, os genes anarquistas de papai passaram pro playboi aqui ...